{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-070899","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.284021+00:00","generated_at":"2026-05-21T08:57:41.928754+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ARS Pharma Q1 neffy revenue $7.8M, net loss $33.9M; commercial progress with 5,000+ prescribers","bullets":["Net product revenue of $7.8M from neffy; total revenue $8.0M; net loss $33.9M ($0.35 per share).","Cash, equivalents and investments $275.7M; company says runway adequate for over three years.","More than 5,000 HCPs prescribed neffy; co-promotion with ALK expands reach to ~20,000 HCPs including pediatricians.","57% commercial coverage secured; neffy 1mg now available for children 4+ weighing 15-30 kg.","Regulatory decisions expected mid-2025 in UK, year-end in Canada; German launch mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-070899","json":"https://secwatch.observer/filing/0000950170-25-070899.json","markdown":"https://secwatch.observer/filing/0000950170-25-070899.md","text":"https://secwatch.observer/filing/0000950170-25-070899.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000095017025070899/0000950170-25-070899-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000095017025070899/spry-20250514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T08:57:41.928754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}